glp1 vs semaglutide vs tirzepatide glp 1 Curious about the differences between today's most popular GLP-1 medications? Here's your quick guide to semaglutide, tirzepatide, and retatrutide — three powerful tools on the Semaglutide vs. Tirzepatide: Which GLP-1

Maybe not visibly

Saxenda (Liraglutide) FDA approval: 2014 for chronic weight management Indicated population: Adults with BMI 30, OR Adults with BMI 27 with at least one weight-related condition Also available as: Victoza (lower dose, approved for Type 2 diabetes) Ozempic (Semaglutide) FDA approval: 2017 for Type 2 diabetes Indicated population: Adults with Type 2 diabetes as adjunct to diet and exercise Not approved for: Weight loss (though commonly prescribed off-label) Wegovy (Semaglutide) FDA approval: 2021 for chronic weight management Indicated population: Adults with BMI 30, OR Adults with BMI 27 with at least one weight-related condition Adolescents aged 12+ with obesity Same medication as Ozempic: Different dosing and FDA indication Practical Implications The regulatory distinctions matter for: Insurance coverage: Medications are often covered only for their approved indications

One day of slightly higher drug levels does not accelerate or impede fat loss in any measurable way

Semaglutide reduces appetite via GLP-1 receptors

Bundled subscriptions and already-shipped medications are listed as non-refundable in the published terms